Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTEX2/3: Treatment Extension in HCV Genotype 2/3
NCT00803309Phase 4Terminated
- Start
- Nov 2008
- Primary completion
- Aug 2013
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C (HCV) (2 arms). Primary endpoints: Reduction of Relapse rate and Sustained Virological Response. Started Nov 2008; status: terminated.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00803309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00803309.